The results of the above studies constitutes the basis for registration of PD-1 or PD-L1 inhibitors for the treatment of NSCLC after the failure of previous therapies based on platinum derivatives, and also inspired a number of studies analyzing the effect of their use in previously untreated patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.